{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:05Z","timestamp":1791919625051,"version":"4.3.4"},"reference-count":131,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>The last few years have seen a revolution in cellular immunotherapies for multiple myeloma (MM) with novel antigen targets. The principle new target is B\u2010cell maturation antigen (BCMA). Autologous chimeric antigen receptor T\u2010cell (CAR\u2010T) therapy directed against BCMA was first approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2021, although approval by the National Institute for Health and Care Excellent (NICE) is awaited. Initial response rates in patients with heavily pretreated MM have been impressive, but patients are still relapsing. Furthermore, CAR\u2010T manufacturing is expensive and time\u2010consuming, and T\u2010cell fitness is impaired by prior MM treatment. Numerous strategies to improve outcomes and delivery of cellular immunotherapy are under investigation, including next\u2010generation CARs, allogeneic \u2018off\u2010the\u2010shelf\u2019 CARs and targeting of other MM antigens including G protein\u2010coupled receptor, class C, group 5, member D (GPRC5D), Fc receptor homologue 5 (FcRH5), cluster of differentiation (CD)19, signalling lymphocyte activation molecule family member 7 (SLAMF7) and several others. In this exciting and rapidly evolving treatment landscape, this review evaluates the most recent clinical and preclinical data pertaining to these new cellular immunotherapies and explores strategies to overcome resistance pathways. On the protracted journey to a long\u2010term cure, we outline the challenges that lie ahead and ask, \u2018Are we there yet?\u2019<\/jats:p>","DOI":"10.1111\/bjh.19896","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T03:17:15Z","timestamp":1731986235000},"page":"2175-2189","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Are we there yet?\n                    <scp>CAR<\/scp>\n                    \u2010T therapy in multiple myeloma"],"prefix":"10.1111","volume":"205","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-5111","authenticated-orcid":false,"given":"Eitan","family":"Mirvis","sequence":"first","affiliation":[{"name":"School of Cancer &amp; Pharmaceutical Sciences, King's College London  London UK"},{"name":"Department of Haematology King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1434-0594","authenticated-orcid":false,"given":"Reuben","family":"Benjamin","sequence":"additional","affiliation":[{"name":"School of Cancer &amp; Pharmaceutical Sciences, King's College London  London UK"},{"name":"Department of Haematology King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-1005-8"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00900-z"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010022\u201001296\u20102"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01489-3"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26628"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000983"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168996"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034707"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32866-0"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00929-0"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-4-324"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1149138"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010162469"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010146074"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303379"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970460.94543.ab"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010159156"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8025"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00222-X"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010168610"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010163827"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010162395"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00372-6"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01824"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00176-5"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26486"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201022\u20100074"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8005"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02065-x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006699"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010021\u201001170\u20107"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02214-z"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2030476"},{"key":"e_1_2_9_46_1","unstructured":"U.S. Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.2017."},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01365"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010181762"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010164828"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991092"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO20234116_suppl8009"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025945"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2139052"},{"key":"e_1_2_9_55_1","unstructured":"First cell\u2010based gene therapy to treat adult patients with multiple myeloma|European Medicines Agency [Internet].2024. Available from:https:\/\/www.ema.europa.eu\/en\/news\/first\u2010cell\u2010based\u2010gene\u2010therapy\u2010treat\u2010adult\u2010patients\u2010multiple\u2010myeloma"},{"key":"e_1_2_9_56_1","unstructured":"New gene therapy to treat adult patients with multiple myeloma|European Medicines Agency [Internet].2024. Available from:https:\/\/www.ema.europa.eu\/en\/news\/new\u2010gene\u2010therapy\u2010treat\u2010adult\u2010patients\u2010multiple\u2010myeloma"},{"key":"e_1_2_9_57_1","unstructured":"Johnson & Johnson.U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI\u00ae (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma.2024. Available from:https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/u\u2010s\u2010fda\u2010oncologic\u2010drugs\u2010advisory\u2010committee\u2010recommends\u2010carvykti\u2010ciltacabtagene\u2010autoleucel\u2010for\u2010the\u2010earlier\u2010treatment\u2010of\u2010patients\u2010with\u2010relapsed\u2010or\u2010refractory\u2010multiple\u2010myeloma"},{"key":"e_1_2_9_58_1","unstructured":"CARVYKTI\u00ae\u25bc.(ciltacabtagene autoleucel; cilta\u2010cel) is the first BCMA\u2010targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy [Internet].2024. Available from:https:\/\/www.jnj.com\/media\u2010center\/press\u2010releases\/carvykti\u2010ciltacabtagene\u2010autoleucel\u2010cilta\u2010cel\u2010is\u2010the\u2010first\u2010bcma\u2010targeted\u2010treatment\u2010approved\u2010by\u2010the\u2010european\u2010commission\u2010for\u2010patients\u2010with\u2010relapsed\u2010and\u2010refractory\u2010multiple\u2010myeloma\u2010who\u2010have\u2010received\u2010at\u2010least\u2010one\u2010prior\u2010line\u2010of\u2010therapy"},{"key":"e_1_2_9_59_1","unstructured":"Bristol Myers Squibb.U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple\u2010Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy.2024. Available from:https:\/\/news.bms.com\/news\/corporate\u2010financial\/2024\/U.S.\u2010FDA\u2010Approves\u2010Bristol\u2010Myers\u2010Squibb\u2010and\u20102seventy\u2010bios\u2010Abecma\u2010for\u2010Triple\u2010Class\u2010Exposed\u2010Relapsed\u2010or\u2010Refractory\u2010Multiple\u2010Myeloma\u2010After\u2010Two\u2010Prior\u2010Lines\u2010of\u2010Therapy\/default.aspx"},{"issue":"1","key":"e_1_2_9_60_1","first-page":"1","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez\u2010Otero P","year":"2024","journal-title":"Blood Cancer J"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V20.1.202314"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010019\u20100178\u20108"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0087"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39395-4"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.211"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD\u20102023\u2010185085"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03326-6"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30090573"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036814"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14619-z"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010166764"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1080\/19336918.2016.1215785"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015161"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010168968"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102003\u201006\u20102043"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006699"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000703"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20100132"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010165646"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004079"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201023\u20100049"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021429"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0227"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01209-9"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01245-5"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010178954"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102019\u2010129405"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23730"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115691"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010150923"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017848"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04585-5"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0007-1"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2022.03.009"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.832645"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000600"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010137650"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18816"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146518"},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201018\u20101146"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-02959-8"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010410"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-21-0157"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00189"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.04.001"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010157950"},{"issue":"4","key":"e_1_2_9_114_1","first-page":"59","article-title":"UCARTCS1A, an allogeneic CAR T\u2010cell therapy targeting CS1 in patients with relapsed\/refractory multiple myeloma (RRMM): preliminary translational results from a first\u2010in\u2010human phase I trial (MELANI\u201001)","volume":"29","author":"Patel K","year":"2021","journal-title":"Mol Ther"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010189665"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030567"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267475"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2022.01.004"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00365-x"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35127-2"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010159289"},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000596"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031096"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010032"},{"key":"e_1_2_9_126_1","unstructured":"Drug Price Information [Internet].2023. Available from:https:\/\/www.drugs.com\/price\u2010guide\/"},{"key":"e_1_2_9_127_1","unstructured":"Final draft guidance | Project documents | Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333] | Guidance | NICE."},{"issue":"10","key":"e_1_2_9_128_1","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-023-00150-5","article-title":"FDA approves first GPRC5D \u00d7 CD3\u2010targeted bispecific for multiple myeloma","volume":"22","author":"Mullard A","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_2_9_129_1","unstructured":"EMA Recommends Granting a Conditional Marketing Authorisation\u2026 [Internet].2024. Available from:https:\/\/www.esmo.org\/oncology\u2010news\/ema\u2010recommends\u2010granting\u2010a\u2010conditional\u2010marketing\u2010authorisation\u2010for\u2010talquetamab"},{"key":"e_1_2_9_130_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_9_131_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41"},{"key":"e_1_2_9_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19896","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.19896","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T22:10:51Z","timestamp":1771107051000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":131,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/bjh.19896"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19896","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"2024-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}